Neuren Pharma - Public Comps and Valuation Multiples

Neuren Pharma Overview

About Neuren Pharma

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.

Founded

2004

HQ

Employees

Website

neurenpharma.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

LTM Revenue $74.8M

LTM EBITDA $44.1M

EV

$1.4B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Neuren Pharma Financials

As of August 2025, Neuren Pharma reported last 12-month revenue of $74.8M and EBITDA of $44.1M.

In the same period, Neuren Pharma achieved $37.6M in LTM net income.

See Neuren Pharma valuation multiples based on analyst estimates

Neuren Pharma P&L

In the most recent fiscal year, Neuren Pharma reported revenue of $140M and EBITDA of $115M.

Neuren Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Neuren Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$74.8M	XXX	$140M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$140M	XXX	XXX	XXX
Gross Margin	n/a	XXX	100%	XXX	XXX	XXX
EBITDA	$44.1M	XXX	$115M	XXX	XXX	XXX
EBITDA Margin	59%	XXX	82%	XXX	XXX	XXX
EBIT	$44.2M	XXX	$115M	XXX	XXX	XXX
EBIT Margin	59%	XXX	82%	XXX	XXX	XXX
Net Profit	$37.6M	XXX	$93.1M	XXX	XXX	XXX
Net Margin	50%	XXX	67%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Neuren Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $74.8M. EBITDA for the last twelve months was $44.1M. In the most recent fiscal year, Neuren Pharma achieved $140M in revenue and $115M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$74.8M	Analyst estimates available to subscribers	$140M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$140M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	100.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$44.1M	Analyst estimates available to subscribers	$115M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	58.9% EBITDA margin	Analyst estimates available to subscribers	82.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$44.2M	Analyst estimates available to subscribers	$115M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	59.0% EBIT margin	Analyst estimates available to subscribers	82.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$37.6M	Analyst estimates available to subscribers	$93.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	50.2% net profit margin	Analyst estimates available to subscribers	66.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Neuren Pharma

This financial data table provides comprehensive performance metrics for Neuren Pharma, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Neuren Pharma generated $74.8M in revenue over the last twelve months.
The company achieved $44.1M in EBITDA over the last twelve months.
Net income over the last twelve months reached $37.6M.

Fiscal Year Performance

In the most recent fiscal year, Neuren Pharma reported $140M in total revenue.
Fiscal year EBITDA was $115M.
The company maintained a gross profit margin of 100.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 82.3%.
Net profit margin reached 66.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Neuren Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Neuren Pharma Stock Performance

Neuren Pharma has current market cap of AUD 2.4B (or $1.6B), and EV of AUD 2.1B (or $1.4B).

Market Cap Evolution

Neuren Pharma Stock Data

As of September 16, 2025, Neuren Pharma's stock price is AUD 19 (or $13).

See Neuren Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.4B	$1.6B	XXX	XXX	XXX	XXX	$0.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Neuren Pharma Valuation Multiples

Neuren Pharma's trades at 10.1x EV/Revenue multiple, and 12.2x EV/EBITDA.

See valuation multiples for Neuren Pharma and 15K+ public comps

Neuren Pharma Financial Valuation Multiples

As of September 16, 2025, Neuren Pharma has market cap of $1.6B and EV of $1.4B.

Equity research analysts estimate Neuren Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Neuren Pharma has a P/E ratio of 42.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.6B	XXX	$1.6B	XXX	XXX	XXX
EV (current)	$1.4B	XXX	$1.4B	XXX	XXX	XXX
EV/Revenue	18.8x	XXX	10.1x	XXX	XXX	XXX
EV/EBITDA	31.9x	XXX	12.2x	XXX	XXX	XXX
EV/EBIT	31.8x	XXX	12.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	42.6x	XXX	17.2x	XXX	XXX	XXX
EV/FCF	25.6x	XXX	-190.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Neuren Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Neuren Pharma Margins & Growth Rates

Neuren Pharma's last 12 month revenue growth is 6%

Neuren Pharma's revenue per employee in the last FY averaged $7.4M, while opex per employee averaged $1.3M for the same period.

Neuren Pharma's rule of 40 is 91% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Neuren Pharma's rule of X is 73% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Neuren Pharma and other 15K+ public comps

Neuren Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	6%	XXX	-18%	XXX	XXX	XXX
EBITDA Margin	59%	XXX	82%	XXX	XXX	XXX
EBITDA Growth	-25%	XXX	-66%	XXX	XXX	XXX
Rule of 40	91%	XXX	88%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	73%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$7.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	18%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial